首页> 外文期刊>Expert opinion on biological therapy >Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
【24h】

Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

机译:非小细胞肺癌靶向治疗的预后和预测性生物标志物:谁为之付出代价?

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: The discovery of molecular biomarkers and the advent of targeted therapies have led to a radical change in the treatment of several tumors, including NSCLC. In the last few years, the number of molecular biomarkers has rapidly increased, and a growing interest has been recently focused on their potential prognostic and predictive value in clinical settings.
机译:简介:分子生物标志物的发现和靶向疗法的出现导致包括NSCLC在内的多种肿瘤的治疗发生了根本性变化。在过去的几年中,分子生物标志物的数量迅速增加,并且最近人们对它们在临床环境中的潜在预后和预测价值的关注日益增长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号